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Abstract
Introduction: Although human epidermal growth factor receptor 2 (HER2) positive or estrogen receptor (ER)
positive breast cancers are treated with clinically validated anti-HER2 or anti-estrogen therapies, intrinsic and
acquired resistance to these therapies appears in a substantial proportion of breast cancer patients and new
therapies are needed. Identification of additional molecular factors, especially those characterized by aggressive
behavior and poor prognosis, could prioritize interventional opportunities to improve the diagnosis and treatment
of breast cancer.
Methods: We compiled a collection of 4,010 breast tumor gene expression data derived from 23 datasets that
have been posted on the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO)
database. We performed a genome-scale survival analysis using Cox-regression survival analyses, and validated
using Kaplan-Meier Estimates survival and Cox Proportional-Hazards Regression survival analyses. We conducted a
genome-scale analysis of chromosome alteration using 481 breast cancer samples obtained from The Cancer
Genome Atlas (TCGA), from which combined expression and copy number data were available. We assessed the
correlation between somatic copy number alterations and gene expression using analysis of variance (ANOVA).
Results: Increased expression of each of the heat shock protein (HSP) 90 isoforms, as well as HSP transcriptional
factor 1 (HSF1), was correlated with poor prognosis in different subtypes of breast cancer. High-level expression of
HSP90AA1 and HSP90AB1, two cytoplasmic HSP90 isoforms, was driven by chromosome coding region
amplifications and were independent factors that led to death from breast cancer among patients with triple-
negative (TNBC) and HER2-/ER+ subtypes, respectively. Furthermore, amplification of HSF1 was correlated with
higher HSP90AA1 and HSP90AB1 mRNA expression among the breast cancer cells without amplifications of these
two genes. A collection of HSP90AA1, HSP90AB1 and HSF1 amplifications defined a subpopulation of breast cancer
with up-regulated HSP90 gene expression, and up-regulated HSP90 expression independently elevated the risk of
recurrence of TNBC and poor prognosis of HER2-/ER+ breast cancer.
Conclusions: Up-regulated HSP90 mRNA expression represents a confluence of genomic vulnerability that renders
HER2 negative breast cancers more aggressive, resulting in poor prognosis. Targeting breast cancer with up-
regulated HSP90 may potentially improve the effectiveness of clinical intervention in this disease.
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Introduction
Despite the progress that has been made in reducing
mortality rates of breast cancer in the most recent time
period, more than 40,000 breast cancer deaths occur in
the United States annually [1]. Substantial progress in
treatment requires identification of a specific set of
actionable genomic abnormalities that drive or facilitate
tumorigenesis, resistance to a given treatment and
recurrence. Although significant amounts of gene
expression profile analyses have been performed in
breast cancers, assessing expression levels as the primary
parameter to characterize breast cancers may be con-
founded by the phenotypic heterogeneity that arises as a
consequence of abnormal signaling nodes and extensive
biological cross-talk and redundancy. On the other
hand, copy number aberrations in cancer cells can
quantitatively affect gene function [2], and multiple copy
number aberrations collectively regulate clinical pheno-
types and cancer prognosis [3]. Analyses of chromoso-
mal copy number aberrations (CNAs) have been
proposed as a critical indicator of the possible location
of aggressive cancer phenotype related genes [4,5].
Therefore, we undertook an integrative analysis of copy
number and gene expression in a large population study
to identify molecular factors abundant in breast cancer
cells, especially in those characterized by aggressive
behavior and poor prognosis, by which to prioritize
interventional opportunities to transform breast cancer
diagnosis, characterization, treatment and ultimately
prevention.
Although a number of aberrant signaling pathways in
breast cancer have been identified, heat shock protein
90 (HSP90), which is one of the most abundant proteins
in mammalian cells [6], plays an important role in fold-
ing newly synthesized proteins or stabilizing and refold-
ing denatured proteins after stress, and would influence
a large number of signaling pathways. To date, more
than 200 HSP90 clients have been identified, including
key regulators in signal transduction and cell cycle con-
trol, steroid hormone receptors, and tyrosine and serine/
threonine kinases [7-9]. HSP90 exists as multiple iso-
forms that include HSP90AA1 (an inducible form) and
HSP90AB1 (a constitutive form) in cytoplasm, HSP90B1
in endoplasmic reticulum and TRAP1 in mitochondria
[10]. However, unlike HSP90AA1 and HSP90AB1, the
client proteins selectively interacting with HSP90B1 or
TRAP1 chaperones have yet to be defined.
HSP90 contains an N-domain ATP binding site and
its ATPase activity is necessary for all of its cellular
functions [11]. In vivo Hsp90 does not function alone
but acts in concert with co-chaperones such as Sba1/
p23 and Cdc37[8]. Interactions with co-chaperones are
thought to be important to direct Hsp90 function for
specific physiological processes such as regulation of cell
cycle progression, apoptotic responses, or kinase-
mediated signaling cascades [10]. The protein is regu-
lated both at the expression level and through posttran-
slational modifications such as phosphorylation,
acetylation and methylation. These processes control its
ATPase activity, and its ability to interact with its clients
and co-chaperones, as well as its degradation [6,7]. In
addition, HSP90 has a higher affinity for amino–term-
inal ligands in cancer cells, compared with the HSP90 in
normal cells[12].
In breast cancer, HSP90 is required for the stabiliza-
tion of many proteins in pathways that play key roles in
cancer growth and survival, such as estrogen receptor
(ER), progesterone receptor (PR), essential components
of HER2 signaling (HER2, AKT, c-SRC, RAF and HIF-
1a), and EGFR [9,13]. For example, HER2 is among the
most sensitive client proteins of HSP90 [14,15], and
HSP90 inhibition mediates degradation of HER2, as well
as PI3K and AKT in HER2-overexpressing cancer cells
[16]. Consequently, HSP90 inhibitors plus trastuzumab
have significant anticancer activity in patients with
HER2-positive, metastatic breast cancer previously pro-
gressing on trastuzumab[17]. Although a number of
agents are in development for HER2+ and ER+ breast
cancers, HSP90 inhibitors also represent therapeutic
opportunities in other molecular subtypes. Triple nega-
tive breast cancer (TNBC) is defined by the clinical
laboratory evaluation revealing a lack of expression of
ER, PR and HER2 receptors, accounts for 10% to 20% of
all breast cancer[18], and has a higher rate of distant
recurrence and a poorer prognosis than other breast
cancer subtypes [19,20]. Unfortunately, the lack of
expression of a credentialed therapeutic target in this
subtype of breast cancer limits the effective treatment
options. Of interest, TNBCs often express increased
EGFR protein, but in early clinical trials, response rates
to EGFR inhibitors were minimal.
One potential therapeutic opportunity in tumor sub-
types that do not have a known therapeutic target could
include targeting Hsp90 function. Although Hsp90 pro-
tein expression was reported to be relatively low in
TNBC compared to other subtypes, this early report
only evaluated nine tumors [21]. More encouragingly, in
pre-clinical models, TNBCs have been sensitive to
Hsp90 inhibitors [22,23]. Similarly to HER2 positive
tumors, TNBCs were sensitive to Hsp90 inhibition
through down-regulation of components of the Ras/Raf/
MARK pathway in preclinical and in vitro studies [23].
Being a central integrator of multiple pathways, activa-
tion of HSP90 may maintain the malignant phenotype,
facilitate metastasis, and promote treatment-resistance
under the stress of cancer therapy in multiple breast
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cancer subtypes. It has been suggested that Hsp90 up-
regulation may be a sign of poor disease prognosis [24]
and a recent study has demonstrated that co-expression
of HSP90 and PI3K or expression of HSP90 in combina-
tion with the loss of PTEN were associated with signifi-
cantly worse recurrence-free survival in patients with
breast cancer [25]. However, adequately powered popu-
lation studies correlating up-regulated HSP90 with prog-
nosis in breast cancer patients have not been performed
to date.
In this study, we exploited the availability of publicly
available data and performed a genome scan for somatic
copy number aberrations and gene expression profiling
of primary breast tumors to address the general prog-
nostic significance of gene amplification and high-level
expression in breast cancer. We found that up-regulated
HSP90 was one of the most significant poor prognosis
factors in triple negative and HER2-/ER+ breast cancer
subtypes. Our result suggested that targeting breast can-
cer with up-regulated HSP90 would potentially reduce
the risk of lethal recurrence and distant metastasis.
Materials and methods
Human breast tumor samples and data collection
A total of 4,010 breast cancer gene expression profiles
were collected from 23 independent data sets
(GSE22093, GSE17705, GSE11121, GSE12093, GSE7390,
GSE5327, GSE6532, GSE1456, GSE2034, GSE3494,
GSE26639, GSE20685, GSE23720, GSE21653,
GSE16446, GSE23177, GSE19615, GSE12276, GSE9195,
GSE17907, GSE16391, GSE22035 and GSE5460) that
were on NCBI Gene Expression Omnibus (GEO). Pri-
mary breast tumor samples were obtained before treat-
ment and gene expression profiles were measured using
Affymetrix U133A or U133 Plus 2.0 expression array.
Each dataset selected for this study should have either
clinical outcome data and/or HER2, ER or PR status
determined by immunohistochemistry (Additional file
1). Patients’ unique IDs were also collected from series
matrix files (GEO) to ensure there is no redundant sam-
ple set. In addition, we successfully processed somatic
copy number alterations (CNAs) of 481 breast invasive
carcinoma samples that were measured using Affymetrix
Genome-Wide Human SNP Array 6.0, of which gene
expression profiles of the same set of primary tumor
samples were also measured using Agilent Expression
244 K microarrays by The Cancer Genome Atlas Project
(TCGA).
Processing of gene expression data
Raw Affymetrix expression CEL files from each dataset
were RMA (Robust Multi-array Average) normalized
independently using Expression Console Version 1.1
(Affymetrix). All data were filtered to include those
probes on the HG-U133A platform. Assuming that the
signal from the 69 Affymetrix control probes should be
invariant, we found the structure in those probes by tak-
ing the first 15 principal components, and then removed
the contribution of those patterns in the expression of
genes using Bayesian Factor Regression Modeling
(BFRM) [26]. A Principal Component Analysis (PCA)
and Heatmap were used to confirm dataset normaliza-
tion (Figure 1 and Additional file 2). By this procedure,
we generated a normalized gene expression dataset
compiling 4,010 breast tumor samples.
Copy number analyses
Somatic copy number alterations (CNAs) of invasive
breast cancer samples collected from 517 female
patients were measured using Affymetrix Genome-Wide
Human SNP Array 6.0. CEL files were available from
TCGA. SNP array data from matched blood lympho-
cytes or matched normal tissue were also available for
494 patients. We generated a canonical genotype cluster
using a data set of 799 Affymetrix Genome-Wide
Human SNP 6.0 arrays that measured from normal
blood lymphocytes obtained from TCGA. In total,
1,831,105 SNP and copy number markers were analyzed
to construct canonical clustering positions and Log R
ratio (LRR) and B allele frequency (BAF) from raw CEL
files were calculated using PennCNV-Affy [27]. Matched
normal samples were genotyped using Affymetrix geno-
typing console (version 4) and all samples were com-
pared to ensure there was no duplication. All copy
number markers and SNPs with genotype call rate
higher than 90% were selected for tumor copy number
analysis, and CNA calls were generated using genoCN
software [28]. Genotype calls from normal tissues of the
same individual were applied for genoCNA analysis, if
they were available. Thirty-six samples that failed to
obtain estimated parameters after 200 iterations of EM
were removed from further study. All probe coordinates
were mapped to the human genome assembly build 36
(hg18). In total, tumor copy number on chromosome 1-
22 and chromosome X were successfully measured in
481 TCGA breast tumor samples, and normalized gene
expression data from the same set of samples were
downloaded from TCGA.
Statistics analyses
We downloaded the Affymetrix U133A annotation file
(hg18) from Affymetrix and removed probe sets that do
not have a matched gene symbol or whose probe set’s
alignment did not match with gene chromosome loca-
tion (pseudogenes). Using all 4,010 samples, we defined
the gene expression level at each probe set as low-level
expression (bottom 10% low expression value), inter-
mediate-level expression (middle 80% expression value)
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and high-level expression (top 10% high expression
value), and compared survival differences among those
three groups using Cox-regression survival analyses. Co-
efficiency was used to ensure if high-level expression
was associated with poor prognosis and low-level
expression was correlated with better outcome. A total
of 11,761 known genes were analyzed. Statistical ana-
lyses were performed using R Project for Statistical
Computing (Augasse, Austria), Matlab (Natick, MA,
USA) or STATISTICA (Tulsa, OK, USA). Kaplan-Meier
survival analyses on selected genes were conducted
using GraphPad (La Jolla, CA, USA).
To measure the correlation between copy number
aberration and gene expression, we generated copy
number calls at 1,794,774 probes on chromosome 1-22
and chromosome X from all samples, including 857,551
SNPs and 937,223 CN markers. We determined copy
number calls at each marker site as homozygous dele-
tion (CN = 0), hemizygous deletion (CN = 1), normal
copy number (CN = 2), low level amplification (CN = 3)
and high level amplification (CN ≥4). We downloaded
normalized expression data (level 2) from the TCGA
database and analyzed the association between copy
number and gene expression using analysis of variance
(ANOVA). Associated region was defined as the region
that should cover at least five consecutive SNPs or CN
markers and should be longer than 10 kb. Direct corre-
lation was defined as amplification associated with high-
level expression and deletion was correlated with low-
level expression.
Results
Analysis of 4,010 breast cancer samples
To conduct a genome wide survey for poor prognosis-
associated genes in breast cancer, we compiled a collection
of breast tumor gene expression data (n = 4,010) derived
from 23 datasets that were posted on the NCBI Gene
Expression Omnibus (GEO, Table 1) and normalized by
Bayesian Factor Regression Modeling (BFRM) to remove
technical variation (Figure 1A; Additional file 2) [26]. In
addition to the raw expression data, we also obtained clini-
cal outcome data from a subset of the samples (Additional
file 1), which included data on overall survival (n = 1,027),
recurrence-free survival (n = 1,372), and distant metastasis
free survival (n = 2,187), as well as disease specific survival
(event of death from breast cancer, n = 395).
As shown in Table 1, the majority of samples lacked
the molecular analysis of HER2, ER and PR expression
as measured by immunohistochemistry (IHC) or fluores-
cent in situ hybridization (FISH) analysis. Nevertheless,
we found significant correlations between mRNA
expression level and reported HER2, ER or PR status
measured by IHC (P < 1 × 10-8, Mann-Whitney U test,
Additional file 3), which was consistent with previous
reports that ER, HER2 and PR biochemical status was
concordant with Affymetrix microarray data [29,30]. By
Figure 1 Analysis of 4,010 breast cancer sample. (A) PCA plots of before normalization and after normalization. These plots show the gene
expression profiles of the samples plotted on the first two principal components. Each point represents a sample, and samples from the same
data set have the same color. If there are batch effects, the samples from the same data set (the same color) will cluster together. If there are no
batch effects, the colors should be mixed. (B) Prediction of HER2+, TNBC and HER-/ER+ breast cancer subtypes using HER2, ER and PR mRNA
expression levels.
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fitting two normal distributions of mRNA expression
into IHC positive and negative groups, we identified a
bimodal cutoff that represents maximum likelihood of
IHC status, using samples where the biochemical status
of HER2 (n = 1,004), ER (n = 2,771) and PR (n = 1,559)
was available [29], and then applied this predictive cutoff
to the entire set of 4,010 samples (Additional file 4).
Clinical outcomes of gene expression defined subtypes
were highly concordant with IHC subtypes (Additional
file 4). When mRNA expression of HER2, ER and PR
were applied together, the over-all accuracy for HER2+,
triple-negative and HER2-/ER+ was 91.7%, 91.5%, and
89.6%, respectively, comparing with the biochemical
defined breast cancer subtypes (Figure 1).
Genome-scan of copy number aberration in 481 breast
cancer samples
Chromosomal aberrations reflect oncogene activation
and loss of tumor suppressor genes. Surveys of DNA
gain or loss have been considered a fertile area to
search for determinants of treatment response and
disease outcome in human cancer cells. In breast can-
cer, it has been reported that 44% to 62% of highly
amplified genes were over-expressed [31,32] and at
least 12% of the total variation in gene expression was
directly attributed to copy number aberrations [33].
TCGA data provide a unique opportunity to enable
different and potentially complementary forms of ana-
lysis of cancer phenotypes given the comprehensive
nature of the datasets generated in this effort. We
were particularly interested in the opportunity to link
genomic copy number alterations with the observed
gene expression profile and clinical data as a strategy
to identify genomic determinants of poor prognosis.
We therefore performed a genome-scale analysis of
chromosome alteration using 481 breast cancer sam-
ples obtained from the TCGA project, from which
combined expression and copy number data were
Table 1 Summary of 23 data sets.
Data set Institution Array Platform number of
array
prognosis IHC Ref.
GSE22093 UT MD Anderson, TX, USA HG-U133A 82 ER [43]
GSE17705 Nuvera Biosciences, MA, USA HG-U133A 298 dmfs ER [44]
GSE11121 Bayer Technology Services GmbH, Leverkusen,
Germany
HG-U133A 200 dmfs [45]
GSE12093 Veridex LLC, CA, USA HG-U133A 136 dmfs [46]
GSE7390 Institut Jules Bordet, Bruxelles, Belgium HG-U133A 198 os, rfs, dmfs ER [47]
GSE5327 University of Chicago, IL, USA HG-U133A 58 dmfs [48]
GSE6532 Institut Jules Bordet, Bruxelles, Belgium HG-U133A, HG-
U133_Plus_2
414 rfs, dmfs ER, PR [49]
GSE1456 Karolinska Institutet, Stockholm, Sweden HG-U133A 159 os, rfs, dmfs,
Death_fromBC
[50]
GSE2034 Veridex, CA, USA HG-U133A 286 rfs ER [51]
GSE3494 Genome Institute of Singapore, Singapore HG-U133A 251 Death_fromBC ER, PR [52]
GSE26639 Institut Curie, Paris, France HG-U133_Plus_2 226 HER, ER,
PR
[53]
GSE20685 Koo Foundation SYS Cancer Center, Taiwan HG-U133_Plus_2 327 os, mfs [54]
GSE23720 Institut Paoli-Calmettes, Marseille, France HG-U133_Plus_2 197 ER, PR [55]
GSE21653 Institut Paoli-Calmettes, Marseille, France HG-U133_Plus_2 266 dmfs HER2, ER,
PR
[56]
GSE16446 Institut Jules Bordet, Bruxelles, Belgium HG-U133_Plus_2 120 os, dmfs HER2, PR [57]
GSE23177 Flanders Institute for Biotechnology, Leuven,
Belgium
HG-U133_Plus_2 116 HER2, ER [58]
GSE19615 Dana-Farber Cancer Institute, MA, USA HG-U133_Plus_2 115 dmfs HER2, ER,
PR
[59]
GSE12276 Erasmus Medical Centre, Rotterdam, Netherlands HG-U133_Plus_2 204 rfs [60]
GSE9195 Institut Jules Bordet, Bruxelles, Belgium HG-U133_Plus_2 77 rfs, dmfs ER, PR [61]
GSE17907 Institut Paoli-Calmettes, Marseille, France HG-U133_Plus_2 55 mfs HER2, ER,
PR
[62]
GSE16391 Institut Jules Bordet, Bruxelles, Belgium HG-U133_Plus_2 55 rfs HER2, ER,
PR
[63]
GSE22035 Centre Rene Huguenin, SAINT-CLOUD, France HG-U133_Plus_2 43 ER [64]
GSE5460 Dana-Farber Cancer Institute, MA, USA HG-U133_Plus_2 127 HER2, ER [65]
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available. We revealed the distribution of copy num-
ber amplifications and deletions across the entire gen-
ome (Figure 2). As expected, we observed that 23.7%
of breast cancer samples had amplification (CN ≥3)
on the HER2 coding region. Although copy number
abnormalities on chromosome 1, 8, 11 and 16 are
more common in studied populations (n = 481), we
found that in most chromosome regions, both ampli-
fications (CN ≥3) and deletions (CN ≤1) occurred in
approximately 10% of analyzed samples (Figure 2).
Identification of genes that were correlated with risk of
death from breast cancer
The large cohort of 4,010 gene expression samples pro-
vided an opportunity to define a subpopulation of
patients containing either extremely high or low expres-
sion levels of candidate genes and to identify genes
whose high-level expression is predominant in a poor
prognosis stage compared to a better prognosis stage.
To determine poor prognosis-associated genes, we per-
formed two stage analyses. In the first stage, we selected
Figure 2 Correlation of HSP90 expression and coding region copy number aberrations. (A) Genome scans for poor prognosis associated
gene. Correlation between gene expression and risk of death from breast cancer was assessed using Cox-regression survival analyses. Direct
correlation is high-level expression was associated with poor survival. Inverse correlation is high-level expression was associated with better
outcome. The y axis represents the level of significance for each expression probe set (log-transformed P values) at the relative genomic position
on each chromosome along the x axis from the short-arm terminus (left) to the long-arm terminus (right). Bottom panel shows somatic CNA
distribution across entire genome. (B) Genome scans for somatic CNA distribution and its correlation with HSP90 and HSF1 expression. Upper
panel shows percentage of amplification (low-level and high-level amplification) and deletion (homozygous and hemizygous deletion) at each
detected chromosome region in a group of 481 breast cancer patients. Bottom panel shows correlation between CNA and HSP90 and HSF1
mRNA expression. ERBB2 was used as positive control. Analysis of variance (ANOVA) was performed to test for association between copy
numbers and gene expression. (C) Scatterplots of correlation between mRNA expression and copy numbers of select genes: homozygous
deletion (0), hemizygous deletion (1), normal copy number (2), low level amplification (3) and high level amplification (≥4), measured by ANOVA
analysis. Circles represent average levels. Vertical bars represent 0.95 confidence intervals.
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a universal cut-off and assigned each of the 4,010 sam-
ples into low, intermediate and high expression cate-
gories for each of 11,761 known genes. Then, we carried
out an unbiased, genome wide Cox-regression survival
analysis, comparing the prognosis difference among
those three groups. By doing this, poor prognosis-asso-
ciated genes should show a poor prognosis in the high
expression group and a better outcome in the low
expression group. In the second stage, we further
assessed the poor prognosis correlation of the identified
genes using gene-expression as a continuous variable
and sought to correlate copy number aberrations with
gene expression by measuring if amplification was corre-
lated with high-level expression and deletion was asso-
ciated with low-level expression.
Starting with the extreme, we defined the lowest 10%
of expression values across the entire 4,010 samples as
low-level expression and the highest 10% of expression
values as high-level expression. Using death from breast
cancer as the incident event, we carried out a genome
wide Cox-regression survival analysis and identified 152
genes whose high-level expression was significantly asso-
ciated with higher risk of death from breast cancer (P <
0.01, Figure 2 and Additional file 5). In addition, we
assigned each of the 4,010 samples into first quartile
(lowest 25%), second quartile (intermediate 50%) and
third quartile (highest 25%) subgroups according to the
expression levels of the 152 identified genes, and com-
pared prognosis differences among these subgroups.
Furthermore, we applied expression signal as a continu-
ous variable to measure the distribution of the identified
genes. A total of 47 of the 152 genes showed linear cor-
relation between increased expression and poor prog-
nosis. The highest risk of death from breast cancer was
observed in patients with either top 10% or 25% higher
level gene expression (P < 0.05, Additional file 5).
Since amplifications or deletions are likely to control
the expression of genes within the corresponding region,
and the correlation between copy number and expres-
sion has been recently suggested as an approach to pre-
dict the authentic molecular drivers in carcinogenesis
[34], we then extended this analysis of gene expression
to assess the correlation between somatic copy number
alterations and gene expression using 481 invasive breast
cancer samples obtained from TCGA. We found that 26
of 47 poor prognosis-associated genes showed a signifi-
cant correlation between copy number aberrations and
mRNA expression (P < 1 × 10-8, ANOVA, Additional
file 5 and Additional file 6). To support this modeling,
we analyzed the expression of HER2, a well known
oncogene associated with poor prognosis based on
increased copy number and high gene expression. As
expected, high-level expression of HER2 was driven by
coding region amplification and was significantly
associated with poor prognosis (Additional file 5).
Importantly, we found both cytoplasmic HSP90 iso-
forms, HSP90AA1 and HSP90AB1, were among the
most significant factors that led to higher risk of death
from breast cancer, indicating that HSP90 plays an
important role in modulating poor prognosis pheno-
types in breast cancer (Additional file 5).
Increasing expression of HSP90 was correlated with poor
prognosis of breast cancer
To address the extent to which HSP90 is a prognostic
factor in breast cancer, we analyzed the correlation
between HSP90 expression and clinical disease out-
comes, such as survival, recurrence, and metastasis, in
different subtypes of breast cancer. Other HSP90 iso-
forms, such as HSP90B1 and TRAP1, may affect treat-
ment responses in specific subtypes of breast cancer and
this effect could be largely diluted in the analysis of a
heterologous population. Therefore, HSP90B1 and
TRAP1, as well as HSP transcriptional factor 1 (HSF1),
were also included.
We assessed the correlation between mRNA expres-
sion and poor prognosis in different breast cancer sub-
types using Cox-regression survival analysis and
compared survival differences between high-level
expression (top 10% or 25%) and low-level expression
groups using Kaplan-Meier Estimated survival analysis.
To elucidate if high-level expression of HSP90 isoforms
were truly independent prognostic factors, we conducted
Cox Proportional-Hazards Regression (COXPH) survival
analyses to quantify the weight of the hazard ratios asso-
ciated with high expression and their significance when
considered alongside other clinical variables, such as
size, grade, nodal status, age, HER2, ER and PR, in the
whole cohort and in the relevant subtype of cancer.
We found that high-level expression of HSP90AA1
independently led to higher risk of death from breast
cancer in TNBC, while HSP90AB1 caused poor survival
among patients with the HER2-/ER+ breast cancer sub-
type through increased risk of distant metastasis (Table
2 and Additional file 7). High-level expression of
HSP90AB1 was an independent factor affecting disease-
specific survival (death from breast cancer) and over-all
survival of breast cancer (Table 2). In addition to these
findings, we found that a higher risk of recurrence in
HER2+ and HER2-/ER+ breast cancer subtypes was sig-
nificantly correlated with increased expression of
HSP90AA1 and HSP90B1; and increasing expression of
HSP90AA1 and HSP90AB1 were significantly associated
with a higher chance of distant metastasis in patients
with HER2-/ER+ tumor (Additional file 7).
Among patients with TNBC, higher expression of
HSP90 isoforms (HSP90AA1, HSP90AB1, HSP90B1 and
TRAP1) was correlated with higher risk of recurrence.
Cheng et al. Breast Cancer Research 2012, 14:R62
http://breast-cancer-research.com/content/14/2/R62
Page 7 of 15
However, these significant interactions were not
observed after adjusted multiple clinical availables. This
might be affected by the fact that the entire set of clini-
cal variables were only available in a small proportion of
the samples. It also indicated that a single HSP90 iso-
form might only have a slight influence on disease out-
come, such that when several interactions occur
together, the combined effect becomes clinically signifi-
cant. Nevertheless, high-level expression of HSF1 was an
independent factor for recurrence in TNBC (Additional
file 7).
Amplifications of HSP90AA1, HSP90AB1 and HSF1
collectively defined a subpopulation of breast cancer
samples with up-regulated HSP90 gene expression
We found a significant association between gene expres-
sion and copy number aberrations in HSP90AA1,
HSP90AB1, TRAP1 and HSF1 (P < 1 × 10-8, ANOVA;
Figure 2) and a trend for significant correlation in
HSP90B1 (P < 1 × 10-5, ANOVA; Figure 2), indicating
that high-level expression of HSP90 and HSF1 was dri-
ven by gene amplification. Although hemizygous dele-
tion of HSP90 isoforms and HSF1 were found in 4.37%
to 18.09% of breast cancer samples, homozygous dele-
tion was uncommon. Only 1 of 481 (2%) breast cancer
samples had two allele deletions on the TRAP1 coding
region, and no patients carried a homozygous deletion
of other HSP90 isoforms and HSF1, suggesting that loss
of expression of HSP90 is a rare event in breast cancer.
We observed that 8% of breast cancer samples carried
amplifications (both high-level and low-level amplifica-
tions, CN ≥3) of HSP90AA1, leading to a higher expres-
sion of HSP90AA1, compared with samples without
HSP90AA1 amplifications (P = 7.67 × 10-8, n = 481,
Mann-Whitney U Test; Figure 3A). Similarly, amplifica-
tions (CN ≥3) of HSP90AB1 were found in 11% of the
population, and were correlated with significantly higher
expression of HSP90AB1 (P = 1.02 × 10-8, n = 481,
Mann-Whitney U Test, Figure 3A). Although amplifica-
tion (CN ≥3) of HSF1 coding regions was a common
event in the studied samples (54.1%), high-level amplifi-
cation (CN ≥4) of HSF1 was found in 16% of the popu-
lation, in which 75% of the samples did not have a co-
amplification of either HSP90AA1 or HSP90AB1 (Figure
3B). Among the samples without amplifications of
HSP90AA1 or HSP90AB1, high-level amplification of
HSF1 was significantly correlated with higher expression
of HSP90AA1 (P = 0.0052, n = 422, Mann-Whitney U
Test) and HSP90AB1 (P = 4.5 × 10-7, n = 428, Mann-
Whitney U Test), respectively (Figure 3A). Furthermore,
amplification of HSP90AA1 and/or high-level amplifica-
tion of HSF1 collectively represents a group of breast
cancer samples with up-regulated HSP90AA1 mRNA
expression (P = 9.62 × 10-8, n = 481, Mann-Whitney U
Test, Figure 3A). Up-regulated HSP90AB1 mRNA
expression was also seen in samples with amplification
of HSP90AB1 and/or high-level amplification of HSF1
(P = 5.72 × 10-14, n = 481, Mann-Whitney U Test, Fig-
ure 3A).
On the other hand, we found that amplification of
HSP90AA1 and HSP90AB1 was a predominant genomic
feature of the highest 10% of HSP90AA1 (P = 0.0001, n
= 481, Fisher’s exact Test) and HSP90AB1 (P = 2.71 ×
10-6, n = 481, Fisher’s exact Test) expressing tumors.
High-level amplification of HSF1 (CN ≥4) was signifi-
cantly enriched in the samples with the highest 20% of
HSF1 (P = 3.30 × 10-10, n = 481, Fisher’s exact Test)
expressing tumors. When samples with the highest 10%
of HSP90AA1 and/or highest 10% of HSP90AB1 expres-
sing tumors were combined with the highest 20% of
HSF1 expressing tumors, this collective set of samples
clearly captured the subpopulation of amplified HSP90
Table 2 Prognosis of HSP90AA1 and HSP90AB1 in different subtypes of breast cancer.
Subtype Gene Cox-regression analysis Kaplan-Meier survival analysis COXPH survival analysis
High 25% vs. others High 10% vs. others High 10% vs. others
P-value n P-value HR(95%CI) P-value HR(95%CI) n P-value P-adjusted n
All samples HSP90AA1 0.0020 395 0.0499 1.75(1.00-3.06) 0.0241 2.81 (1.15-6.90) 395 0.0193 0.3320 225
(dss) HSP90AB1 0.0136 0.0404 1.72(1.02-2.90) 0.0011 3.69 (1.68-8.07) 0.0022 0.0008
All samples HSP90AA1 0.0081 1072 0.0384 1.39(1.02-1.89) 0.0002 2.55(1.55-4.21) 1072 0.0048 0.1069 421
(os) HSP90AB1 0.0175 0.0401 1.36(1.01-1.83) 0.0024 2.06(1.29-3.28) 0.0010 0.0022
HER2+ HSP90AA1 0.7459 194 0.694 0.89(0.50-1.60) 0.1523 2.07(0.76-5.61) 194 0.4364 0.2703 63
(os) HSP90AB1 0.5693 0.6728 1.15(0.59-2.24) 0.3733 1.76(0.51-6.13) 4.90E-08 0.1839
HER2-ER+ HSP90AA1 0.1057 506 0.0706 1.52(0.97-2.39) 0.0563 1.92(0.98-3.75) 506 0.1593 0.5829 228
(os) HSP90AB1 0.0015 0.0918 1.44(0.94-2.20) 0.0005 3.04 (1.63-5.68) 1.53E-05 0.0004
TNBC HSP90AA1 0.0049 282 0.0302 2.07(1.07-3.98) < 0.0001 16.9(4.66-60.9) 282 0.0079 0.0394 105
(os) HSP90AB1 0.1328 0.0483 1.82(1.00-3.30) 0.2936 1.83 0.59-5.66) 0.4344 0.9968
Cox-regression survival analysis was performed using gene expression signal as continuing variable. CI, confidence interval; Dss, disease specific survival (death
from breast cancer); HR, Hazard Ratio; n: number of samples; os, over-all survival.
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(P = 3.99 × 10-25, n = 481, Fisher’s exact Test). Because
high expression of HSP90AA1, HSP90AB1 and HSF1
was driven by amplification, and high-level amplification
of HSF1 was associated with higher expression of
HSP90 in un-amplified HSP90 samples, we defined up-
regulated HSP90 as a collection of samples with the top
10% high expression value of HSP90AA1 and/or
HSP90AB1, and the top 20% higher expression of HSF1.
Using these definitions, up-regulated HSP90 accounted
for 31% of the breast cancer population (Additional file
1) and up-regulated HSP90 was significantly correlated
with higher expression of all HSP90 isoforms (P < 1 ×
10-8, Mann-Whitney U test, Additional file 8).
Up-regulated HSP90 was independently correlated with
poor prognosis in HER2 negative breast cancer subtypes
To investigate the correlation of up-regulated HSP90
and poor breast cancer prognosis, we performed a uni-
variate Kaplan-Meier survival analysis and a multivariate
Cox Proportional-Hazards Regression (COXPH) survival
analysis using other poor clinical outcome-associated
clinical cofactors, such as tumor size, grade, nodal sta-
tus, age, HER2, ER and PRstatus, as co-variants. We
found that up-regulated HSP90 was significantly asso-
ciated with a higher risk of death from breast cancer (P
= 0.0049, n = 395, Figure 3B) and poor overall survival
in a subset of 1,027 patients in which overall survival
Figure 3 Prognosis of up-regulated HSP90. (A) Correlation between HSP90AA1, HSP90AB1 and HSF1 copy number aberrations and HSP90AA1
and HSP90AB1 expression. Differences between up-regulated HSP90 and others were assessed using the exact Mann-Whitney U test. Boxes
represent the 25% to 75% quartiles, lines in the boxes represent the median level, whiskers represent the non-outlier range, and circles represent
the outliers. (B) Distribution of HSP90AA1, HSP90AB1 and HSF1 copy number aberrations across 481 TCGA samples. (C) Prognosis of high-level
expression of HSP90AA1 or HSP90AB1, and up-regulated HSP90. Kaplan-Meier estimates of disease specific survival (event of death from breast
cancer) in 395 breast cancer patients (number of events, n = 83) and over-all survival in 1,027 breast cancer patients (number of events, n =
248). P values were calculated using log-rank Mantel-cox test. Tick marks indicate patients whose data were censored by the time of last follow-
up.
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data were available (P = 0.0034, log-rank Mantel-cox
test, Figure 3C). This poor prognosis phenotype was
independent of clinical cofactors (P = 0.0062, n = 421,
COXPH test, Table 3 and Additional file 9). Further-
more, we found that up-regulated HSP90 was signifi-
cantly associated with a higher risk of recurrence and
distant metastasis in TNBC and breast cancer with the
HER2-/ER+ phenotype (Additional file 10). Up-regulated
HSP90 was an independent factor that led to higher risk
of death from breast cancer in the HER2-/ER+ breast
cancer subtype (P = 0.0042, n = 421, COXPH test,
Table 3), with a trend of significantly higher risk of dis-
tant metastasis in this subtype (Table 3). Particularly,
up-regulated HSP90 independently increased risk of
recurrence in TNBC (P = 0.0101, n = 421, COXPH test,
Table 3; Additional file 9), and more than 70% of TNBC
patients with up-regulated HSP90 had disease recur-
rence within eight years after initial treatment (Addi-
tional file 10).
Discussion
The phenotypic heterogeneity of cancer arises as a con-
sequence of numerous genetic abnormalities (such as
somatic mutations and chromosomal aberrations)
acquired during tumor development and results in the
formation of a disease that is enormously complex and
highly variable between patients. An ability to dissect
this heterogeneity will facilitate a deeper understanding
of the relevance of these alterations for disease pheno-
types by which to develop rational therapeutic strategies
that can be matched with the characteristics of the indi-
vidual patient’s tumor. In fact, this has already been
achieved in some instances of breast cancer where
HER2-positive tumors are treated with trastuzumab or
lapatinib, and ER-positive tumors are treated with anti-
hormonal therapy. To identify additional molecular
characteristics for a more effective treatment of breast
cancer, an approach to rapidly and efficiently leverage
available breast cancer genomic data and correlate both
genetic and clinical features and outcomes is urgently
needed.
Gene expression profiling has become a major tool for
the study of breast cancer and substantial amounts of
data are available from public databases. To date, micro-
array data from more than 6,000 primary breast cancer
samples have been posted on the Gene Expression Omni-
bus (GEO) database. To capture the complexity of breast
cancer heterogeneity and pinpoint molecular factors that
can be therapeutically targeted, we compiled a large col-
lection of breast tumor gene expression data (n = 4,010)
derived from 23 datasets that were published from Octo-
ber 2005 to February 2011, including subsets of samples
in which clinical prognosis data were available. We iden-
tified a series of genes whose high-level expression
increased the risk of death from breast cancer, which
may be exploited to improve the effectiveness of clinical
intervention in this disease. We found that HSP90AA1
and HSP90AB1, two cytoplasmic HSP90 isoforms, were
among the most significant factors of poor prognosis in
different breast cancer subtypes. As one of the most
abundant proteins in malignant cells and a key factor
that stabilizes oncoproteins involved in cancer growth
and survival, our results suggest that increased HSP90
expression may play an important role in promoting
aggressive breast cancer phenotypes. Furthermore, we
found that highly expressed HSP90AA1, HSP90AB1 and
HSF1 were driven by somatic amplifications, which col-
lectively were found in approximately 30% of tumors,
which we classified as up-regulated HSP90. We revealed
that up-regulated HSP90 was significantly associated
with risk of death from breast cancer among patients
with HER2-/ER+ breast cancer, and greatly increased the
chance of disease recurrence in TNBC, and these interac-
tions were independent of clinical variables.
Perhaps the most significant challenge presented by
the complexity of breast cancer is the ability to design
Table 3 Prognosis of up-regulated HSP90 in different subtypes of breast cancer.
Subtype Event phenotype Kaplan-Meier survival analysis COXPH survival analysis
P-value HR (95%CI) n P-value Co-efficiency P-adjusted n
All samples Death 0.0034 1.57 (1.16-2.12) 1072 0.0007 0.5714 0.0062 421
HER2+ Death 0.3118 1.40 (0.73-2.71) 194 0.2564 0.7433 0.1405 63
Recurrence 0.475 0.87 (0.58-1.29) 204 0.9528 -0.2160 0.6705 72
Distant metastasis 0.2292 0.77 (0.50-1.18) 347 0.5383 -0.6461 0.2330 90
HER2-/ER+ Death 0.0148 1.71 (1.11-2.63) 506 0.0003 0.8373 0.0042 228
Recurrence 0.0183 1.31 (1.05-1.65) 832 0.1790 0.2077 0.3054 361
Distant metastasis 0.0002 1.65 (1.27-2.15) 1223 0.0098 0.4050 0.0705 415
TNBC Death 0.0604 1.76 (0.98-3.19) 282 0.5693 0.2586 0.5869 105
Recurrence 0.0002 2.29 (1.49-3.52) 285 0.0008 0.9924 0.0101 122
Distant metastasis 0.0195 1.60 (1.08-2.37) 516 0.6722 -0.0323 0.9390 158
CI: confidence interval; HR: hazard ratio; n: number of samples
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and develop therapeutic regimens that can match the
characteristics of the individual patient’s tumor – to
achieve the goal of personalized cancer treatment. In
addition to the well credentialed or previously described
genes HER2 and GRB7, we found additional factors
associated with an increased risk of death from breast
cancer, such as CUTL1 [35], CTTN [36] and GINS2
[37] that have been previously linked with poor prog-
nosis of breast cancer. This reflects the nature of cancer
heterogeneity in which multiple mutations and altera-
tions generate the cancer phenotype. The development
of therapeutic strategies that can completely and pre-
cisely match the complexity of breast cancer with
equally complex combinations of regimens will be clini-
cally challenging, particularly considering the need to
utilize combinations of drugs that must be shown to be
safe when combined together. A more practical
approach would prioritize the more universal molecular
factors associated with aggressive behavior and poor
prognosis, upon which more general therapeutic regi-
mens can be developed for use in combinations. Pre-
vious reports have indicated that high expression of
HSP90, assessed by protein expression analysis, is asso-
ciated with a poor overall prognosis in breast cancer
patients [24]. High HSP90 expression was associated
with high expression of HER2 and ER, large tumors,
high nuclear grade, and lymph node involvement [9].
Our results demonstrated that up-regulation of multiple
isoforms of HSP90 in primary breast cancer were inde-
pendent poor prognosis factors, indicating that HSP90
targeted therapies in combination with cytotoxic che-
motherapies or other targeted agents, may improve diag-
nosis and treatment of highly aggressive breast cancers.
Because HSP90 is a key component of oncogenic sig-
naling, an increasing number of candidate HSP90 inhibi-
tors have been developed and evaluated, both in
preclinical models and in clinical trials. Although HSP90
inhibitors have exhibited clinical activity in the treat-
ment of breast and other cancers, targeting HSP90
alone generally results in cytostatic rather than cytotoxic
effects on tumors. In the majority of patients, disease
progression occurs following cessation of treatment with
an HSP90 inhibitor [8]. Our results suggest that up-
regulated HSP90 might not be an independent poor
prognosis factor among patients with HER2-positive
breast cancer, as no statistically significant correlation
was observed between poor survival and high-level
expression of any HSP90 isoforms, which is consistent
with the previous finding that the most common clinical
response in patients with HER2-positive breast cancer
who received HSP90 monotherapy is stable disease. In
contrast, multiple studies using cell-based or various
tumor xenograft models of breast cancer have shown a
large degree of synergy by combining HSP90 inhibitors
with therapies targeting HER2 (such as trastuzumab or
lapatinib) [38,39]. Indeed, in animal xenograft models,
tumors often do not immediately re-grow upon drug
withdrawal, and often significant tumor regression can
be observed[17]. In clinical trials, chronic administration
of the majority of HSP90 inhibitors is well tolerated by
humans, with manageable toxicity. At first glance this
seems surprising given the essential role of the protein
in numerous normal cellular processes; however, the
apparent lack of toxicity of HSP90 inhibitors may be
related to the recent realization that cancer cells are
addicted to HSP90–a prime example of tumor cell non-
oncogene addiction [8]. This may provide a sufficiently
large therapeutic window for the safe use of HSP90 inhi-
bitors in cancer. Additionally, there is evidence that
oncogenic clients can alter the conformation of HSP90.
Several inhibitors of the protein have been developed
that only recognize this activated conformation [40,41]
suggesting an even greater therapeutic index.
TNBC has been considered a more aggressive breast
cancer subtype with a higher rate of distant recurrence
and a poorer prognosis [19,20]. We found that increased
expression of each of the HSP90 isoforms was correlated
with a higher risk of recurrence and more than 70% of
patients with up-regulated HSP90 experienced disease
recurrence within eight years after initial treatment, sug-
gesting that TNBC patients might benefit from therapies
that target multiple HSP90 isoforms, such as
HSP90AA1, HSP90AB1 and TRAP1. In fact, in pre-clin-
ical models, TNBC have been sensitive to Hsp90 inhibi-
tors [22,23]. Similar to HER2 positive tumors, TNBCs
were sensitive to Hsp90 inhibition through down-regula-
tion of components of the Ras/Raf/MAPK pathway in
preclinical and in vitro studies [23]. Furthermore, our
results demonstrated that up-regulated HSP90 was also
a significant prognostic factor in HER2-/ER+ breast can-
cers, suggesting a broad application of HSP90 targeted
therapies in the 80% of breast cancers that do not over-
express HER2. In addition, other hormone receptors,
such as androgen receptor, utilized HSP90, which pro-
vides a rationale for the use of HSP90 inhibitors and AR
antagonist in the subset of AR+ breast cancers. Given
the fact that HSP90 is one of the most abundant pro-
teins in breast cancer cells, and HSP90 has been pro-
posed as a potential therapeutic target for other cancers,
including non-small cell lung cancer [42], our results
indicate that HSP90 is an important oncogenic signaling
node in breast cancer, whose high expression is asso-
ciated with aggressive behavior and poor prognosis of
breast cancer. Diagnostic and therapeutic strategies
directed to cancer expressing high levels of HSP90 are
warranted.
Cheng et al. Breast Cancer Research 2012, 14:R62
http://breast-cancer-research.com/content/14/2/R62
Page 11 of 15
Conclusions
High-level expression of two cytoplasmic HSP90 iso-
forms, HSP90AA1 and HSP90AB1, were predominantly
driven by gene amplifications. Using clinical parameters
that were associated with poor clinical outcome, such as
tumor size, grade, nodal status, age, HER2, ER and RP
status, we demonstrated that high-level expressions of
HSP90AA1 and HSP90AB1 were independent poor
prognosis factors affecting triple-negative and HER2-/ER
+ breast cancer subtypes. Furthermore, up-regulated
HSP90 that was defined as a collection of HSP90AA1,
HSP90AB1 and HSF1 amplifications was one of the
most significant factors that independently associated
with risk of death from breast cancer, and greatly
increased the incidence of recurrence and distant metas-
tasis in triple negative and HER2-/ER+ breast cancer
subtypes.
Additional material
Additional file 1: Clinical data of 4,010 breast cancer samples and
expression of selected genes. This table lists clinical data that was
downloaded from NCBI GEO database, and normalized expression signal
of HER2 (216836_s_at), ER (205225_at), PR (208305_at), HSP90AA1
(214328_s_at), HSP90AB1 (214359_s_at), HSP90B1 (200598_s_at) and
HSF1 (213756_s_at), as well as defined up-regulated HSP90.
Additional file 2: Heatmaps. These heatmaps show the expression
patterns in the data before (A) and after (B) normalization. The rows
contain the 1,000 genes that exhibit the highest variance in gene
expression profile across the original data set. The columns contain the
samples in the data sets provided. The genes and samples are in the
same order in both heatmaps. Warm colors indicate high expression of
the gene and cool colors indicate low expression.
Additional file 3: Distribution of HER2, ER and PR mRNA expression
and its correlation with IHC measure molecular status. This figure
shows (A) histograms of HER2, ER and PR mRNA expression in 4,010
breast cancer samples and (B) the correlation between mRNA expression
and IHC status. Differences between positive and negative groups were
assessed using the exact Mann-Whitney U test. Boxes represent the 25%
to 75% quartiles, lines in the boxes represent the median level, whiskers
represent the non-outlier range, and circles represent the outliers.
Additional file 4: Expression defined breast cancer subtypes. This
figure shows (A) Bimodal selection for HER2, ER and PR cutoff according
to the distribution of expression values stratified by IHC/biochemical
status. (B) Distribution of HER2, ER and PR mRNA expression in
combined dataset. (C) Distant metastasis-free survival analyses were
stratified according to IHC/biochemical status or expression derived
status using samples with available IHC/biochemical status and outcome
data. Tick marks in Kaplan-Meier Estimates distant-metastasis free survival
indicate patients whose data were censored by the time of last follow-
up or owing to death. P values were calculated using log-rank Mantel-
cox test.
Additional file 5: Breast cancer poor prognosis associated gene. This
table lists breast cancer poor prognosis -ssociated genes. Cox-regression
survival analyses were performed using 395 samples in which event of
death from breast cancer was available. Analysis of variance (ANOVA) was
performed to test for an association between copy numbers and gene
expression using 481 TCGA breast cancer samples.
Additional file 6: Genome scans for poor prognosis associated
gene. This figure shows the correlation between copy number
aberrations and gene expression of identified genes that were associated
with breast cancer poor prognosis. Upper panel shows percentage of
amplification (low-level and high-level amplification) and deletion
(homozygous and hemizygous deletion) at each detected chromosome
region in a group of 481 breast cancer patients. Bottom panel shows
correlation between CNA and mRNA expression of poor prognosis
associated genes that were identified from each chromosome. Analysis
of variance (ANOVA) was performed to test for association between copy
numbers and gene expression.
Additional file 7: Prognosis of HSP90 and HSF1 in different breast
cancer subtypes. This table lists the results of survival analyses. Breast
cancer subtype specific disease-specific survival (dss, event of death from
breast cancer), over-all survival (os), recurrence-free survival (rfs), and
distant metastasis-free survival (dmfs) were assessed using Cox-regression
survival analysis, Kaplan-Meier Estimates survival analysis and Cox
Proportional-Hazards (COXPH) Regression survival analysis.
Additional file 8: Correlation between HSP90 and HSF1 mRNA
expression and up-regulated HSP90. This figure shows HSP90 and
HSF1 expression difference between samples defined as up-regulated
HSP90 and not up-regulated HSP90. Differences for each pairwise
comparison were assessed by the Mann-Whitney U test. Boxes represent
the 25% to 75% quartiles, lines in the boxes represent the median level,
whiskers represent the non-outlier range, and circles represent the
outliers.
Additional file 9: Cox univariate and multivariate analyses of up-
regulated HSP90. This table lists the results of Cox Proportional-Hazards
(COXPH) Regression survival analyses of up-regulated HSP90 using
samples where the entire set of clinical data was available.
Additional file 10: Prognosis of up-regulated HSP90 in different
breast cancer subtypes. This figure shows Kaplan-Meier estimates curve
of up-regulated HSP90 in different breast cancer subtypes. Number of
recurrence events: TNBC, n = 142; HER2-/ER+, n = 331; HER2+, n = 112.
Number of distant metastasis events: TNBC, n = 133; HER2-/ER+, n = 260;
HER2+, n = 111. Tick marks in Kaplan-Meier estimates of recurrence-free
survival and distant-metastasis free survival indicate patients whose data
were censored by the time of last follow-up or owing to death. P values
were calculated using log-rank Mantel-cox test.
Abbreviations
ANOVA: analysis of variance; CNAs: copy number aberrations; COXPH: Cox
Proportional-Hazards Regression survival analyses; ER: estrogen receptor;
GEO: Gene Expression Omnibus; HER2: human epidermal growth factor
receptor 2; HSF1: HSP transcriptional factor 1; HSP90: heat shock protein 90;
PR: progesterone receptor; RMA: Robust Multi-array Average; TCGA:The
Cancer Genome Atlas; TNBC: triple negative breast cancer.
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